SB Drug Discovery’s TRPML drug discovery platform delivers comprehensive solutions for advancing TRPML1, TRPML2 and TRPML3 research. With advanced cell-based assay capabilities and a full suite of technologies, including fluorescence-based assays, solid-supported membrane electrophysiology, manual patch clamp and automated electrophysiology, we provide robust and flexible options to suit diverse project needs. From hit identification through to lead optimization, our platform ensures high-quality, reproducible data to accelerate TRP channel-targeted drug discovery and drive success at every stage of development.
Introduction
Transient Receptor Potential (TRP) channels are a diverse family of membrane proteins critical for cellular signalling and ion homeostasis. By regulating membrane excitability and intracellular levels of calcium and other ions, TRP channels influence numerous physiological functions. This family is categorized into several subfamilies, including TRPV, TRPM, TRPA, TRPC, and TRPML, each with unique ion selectivity and functional roles.
Among these, the TRPML subfamily, comprising TRPML1, TRPML2, and TRPML3, is distinct for its permeability to Ca²+, Na+, K+, and trace metals such as Fe²+, Mn²+ and Zn²+. Unlike other TRP channels, TRPML channels are located in intracellular compartments such as lysosomes and endosomes, where they regulate ion balance and support membrane trafficking. TRPML1, activated by phosphoinositides, is vital for lysosomal calcium release and overall lysosomal function. Mutations in TRPML1 are linked to mucolipidosis type IV (ML-IV), a neurodegenerative disorder characterized by impaired motor skills.
TRPML channels also play significant roles in immune responses and sensory functions. TRPML2 is predominantly expressed in immune tissues, indicating its involvement in immune regulation, while TRPML3 is found in sensory tissues, including the cochlea and eye, highlighting its contribution to sensory processes. Due to their critical functions, TRPML channels are emerging as promising therapeutic targets for lysosome-related neurodegenerative diseases.
